Replimune Group, Inc (REPL)

Replimune Group (NASDAQ:REPL) reported its Q4 earnings results on Thursday, May 19, 2022 at 08:00 AM. Here's what investors need to ...

Enrollment in the CERPASS clinical trial with RP1 in cutaneous squamous cell carcinoma (CSCC) expected to be completed in mid-year 2022; top line data expected Q1 2023 Directional data from the first 75 patents with 6 months follow up from the IGNYTE clinical trial with RP1 in anti-PD1 failed melanoma expected in late 2022 Phase 2 development plan for RP2/RP3 in HCC, CRC and SCCHN announced WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage bio

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $163.44 per unit.

In this piece, we will take a look at the ten best stocks to buy under $20 according to Jeremy Green’s Redmile Group. If you want to skip the details about the hedge fund, then take a look at the 5 Best Stocks to Buy Under $20 According to Jeremy Green’s Redmile Group. Jeremy Green […]

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $234.60 per unit.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J, ViiV Co-developed ...

RP1 combined with Opdivo® (nivolumab) continues to demonstrate deep and durable responses in patients with melanoma and non-melanoma skin cancers (NMSC); new positive initial data in patients with anti-PD1 failed NMSC Initial data shows clinical activity with RP1 monotherapy in solid organ transplant recipients with cutaneous squamous cell carcinoma (CSCC) Broad Phase 2 development planned for RP2/RP3 in hard-to-treat tumor types Virtual investor event to be held today at 8:00 am ET WOBURN, Mass

Biotech stocks reversed course in the week endingMarch 25, as an increase in risk appetite prompted traders to move money out of ...

Event to begin at 8:00 AM ETWOBURN, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its executive team and Key Opinion Leaders will host an investor event to present updated data from the completed cohorts of the Phase 2 IGNYTE clinical trial in non-melanoma skin cancer (“NMSC”) and melanoma. Additionally, t

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Daily S&P Biotech Bull 3X Shares ETF (LABU), we found that the implied analyst target price for the ETF based upon its underlying holdings is $34.22 per unit.

On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The ...

WOBURN, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference being held virtually on Friday, February 18, 2022 at 8:40 AM ET. A simultaneous webcast will be available in the

Replimune Group (NASDAQ:REPL) reported its Q3 earnings results on Thursday, February 3, 2022 at 08:00 AM. Also check out ...

Data expected to be presented at an investor event in March 2022: Data updates from the completed RP1 IGNYTE cohorts in anti-PD1 naïve non-melanoma skin cancer (NMSC) and anti-PD1 naïve and failed melanoma Initial data from the ongoing study in anti-PD1 failed NMSC and from the ARTACUS trial, a Phase 1b/2 trial of RP1 as monotherapy in solid organ transplant recipients with cutaneous squamous cell carcinoma (CSCC) RP3 initial data and the Phase 2 development plan for RP2/3 WOBURN, Mass., Feb. 03

Investors eyeing a purchase of Replimune Group Inc (REPL) shares, but cautious about paying the going market price of $19.49/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $12.50 strike, which has a bid at the time of this writing of 75 cents..

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Announces ...

WOBURN, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Otello Stampacchia, Ph.D., of Omega Funds, has resigned from the company’s Board of Directors. Dr. Stampacchia joined the Replimune Board in 2015, concurrent with Omega co-leading Replimune’s seed financing. Dr. Stampacchia has resigned to focus his efforts on his growi

During Thursday's morning trading, 152 companies set new 52-week lows. Noteworthy Points From Today's 52-Week ...

CERPASS clinical trial with RP1 in CSCC on track to complete enrollment mid-year with the primary analysis trigger six months thereafter IGNYTE anti-PD1 failed melanoma, evaluating RP1 in combination with Opdivo® on track to release interim data in late 2022 Phase 2 development plan for RP2/3 to be presented in the first quarter of 2022 Replimune to provide corporate update at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022 WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- R

WOBURN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 40th Annual J.P. Morgan Healthcare Conference being held virtually on Monday, January 10, 2022 at 7:30 AM ET. A simultaneous webcast will be available in the Investors section of Repli

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $212.07 per unit.

How far off is Replimune Group, Inc. ( NASDAQ:REPL ) from its intrinsic value? Using the most recent financial data...

Investment company Tekla Life Sciences Investors (Current Portfolio) buys Amgen Inc, Alkermes PLC, Novavax Inc, Intra-Cellular Therapies Inc, AstraZeneca PLC, sells Moderna Inc, Allakos Inc, Blueprint Medicines Corp, Ascendis Pharma A/S, BridgeBio Pharma Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Tekla Life Sciences Investors.

WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of Christy Oliger to the Company’s Board of Directors effective December 1, 2021. “We are delighted to welcome Christy to Replimune’s Board of Directors,” said Philip Astley-Sparke, Chief Executive Officer of Replimune. “Christy brings nearly 30 years of comm

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:EQT) from Equal-Weight to Overweight. For the ...

RP2 data demonstrates deep and durable responses in difficult to treat cancers both as monotherapy and in combination with Opdivo® (nivolumab) Initiated Phase 1 expansion of RP2 in combination with Opdivo focused on patients with liver metastases WOBURN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced updated interim data from the Phase 1 data fr

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good ...

RP1; Full patient accrual in CERPASS registration-directed clinical trial continues to be expected in mid-year 2022 with the primary data trigger expected in late 2022. Interim data in the IGNYTE anti-PD1 failed registration directed melanoma cohort continues to be expected in late 2022 RP2; Updated monotherapy and combination data with Opdivo (nivolumab) to be presented at SITC this month; Phase 1 protocol amendment expansion to add additional patients with liver metastases filed RP2/3; Detaile

WOBURN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences: BMO Biopharma Spotlight Series: Emerging Trends & Therapeutics in OncologyPanel: Pioneering the Next Generation of Oncolytic Virus TherapeuticsDate: Monday, November 8, 2